- Global Pharma News & Resources

Worldwide Tissue Diagnostics Industry to 2025 - Featuring Abbott Laboratories, Agilent Technologies & AstraZeneca Among Others -

DUBLIN--(BUSINESS WIRE)--The "Tissue Diagnostics Market - Forecasts from 2020 to 2025" report has been added to's offering.

The tissue diagnostics market is projected to grow at a CAGR of 7.16% to reach US$6.385 billion by 2025 from US$4.216 billion in 2019.

Cancer is a major public health and economic issue and its burden is set to spiral. With over 18 million cases in 2018, 29 million cases by 2040 are expected due to the aging and growth of the population [Source: WHO]. Recognized as one of the global standards for cancer diagnosis, tissue diagnostics are integral to obtain the biological aspects of tumors. Moreover, with an increased incidence of cancer, the market for tissue diagnostics markets has witnessed a promising growth and is further estimated to grow during the forecast period. Moreover, there is a growing adoption rate pertaining to the automated tissue-based diagnostic systems due to its reported capabilities of swift diagnosis of tumors, by research institutions.

In view of the application, the segment of Lung cancer is the most commonly diagnosed cancer and the leading cause of cancer death worldwide followed by breast cancer. Regarding both sexes combined, globally, lung cancer continues to be the most commonly diagnosed cancer (2.1 million, 12% of the total) and the leading cause of cancer death (1.8 million, 18%) because of its poor prognosis. Female breast cancer is the second most common cancer overall (2.1 million, 12%) but the fifth leading cause of cancer death (627,000, 7%) because of its relatively favorable prognosis. As such, it is the most prevalent cancer worldwide (6.9 million women living within 5 years of their breast cancer diagnosis. About one in twenty females will be diagnosed with breast cancer throughout their lifetime, although this number varies significantly by country. 2 Incidence rates are elevated in Australia/New Zealand, Europe, and North America, notably in Belgium (113 cases per 100,000 female population) and Luxembourg (109) in Europe, and Australia (94).

In contrast, incidence rates in sub-Saharan African regions, particularly in Eastern (30 cases per 100,000 female population) and Middle Africa (28), as well as South-Central Asia (26), were considerably lower. Further, the lifetime risk of breast cancer among females in high-income countries can be up to three times that in low-income countries [ Source: WHO]. To this end, in 2020 Exact Sciences Corp. (NASDAQ: EXAS) announced that it would be presenting data to demonstrate the clinical value of the Oncotype DX Breast Recurrence Score test and exemplify the research progress made by Exact Sciences' Mayo Clinic collaboration toward smarter solutions across the cancer continuum.

Companies Mentioned

  • Abbott Laboratories
  • Agilent Technologies, Inc.
  • AstraZeneca
  • BD
  • BioGenex
  • Cancer Genetics, Inc.
  • Cardinal Health
  • Danaher
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd
  • Genemed Biotechnologies, Inc.
  • Greiner Bio One International GmbH
  • McKesson Medical-Surgical Inc.
  • Medtronic
  • Merck KGaA
  • Thermo Fisher Scientific Inc.

Key Topics Covered:

1. Introduction

2. Research Methodology

3. Executive Summary

4. Market Dynamics

4.1. Market Drivers

4.2. Market Restraints

4.3. Porters Five Forces Analysis

4.4. Industry Value Chain Analysis

5. Tissue Diagnostics Market, By Type

5.1. Introduction

5.2. Consumables

5.2.1. Antibodies

5.2.2. Kits

5.2.3. Probes

5.2.4. Reagents

5.3. Instruments

5.3.1. Slide Scanners

5.3.2. Slide Staining Systems

5.3.3. Tissue Microarrays

5.3.4. Tissue Processing Systems

5.3.5. Others

6. Tissue Diagnostics Market Analysis, By Technology

6.1. Introduction

6.2. Digital Pathology and Workflow Management

6.3. Immunohistochemistry (IHC)

6.4. In Situ Hybridization (ISH)

6.5. Primary Special Staining

7. Tissue Diagnostics Market Analysis, By Application

7.1. Introduction

7.2. Breast cancer

7.3. Cervical cancer

7.4. Colorectal cancer

7.5. Gastric cancer

7.6. Lung cancer

7.7. Others

8. Tissue Diagnostics Market Analysis, By End-User

8.1. Introduction

8.2. Contract Research Organizations (CROs)

8.3. Hospitals

8.4. Pharmaceutical Organizations

8.5. Research Laboratories

9. Tissue Diagnostics Market Analysis, by Geography

9.1. Introduction

9.2. North America

9.3. South America

9.4. Europe

9.5. The Middle East and Africa

9.6. Asia Pacific

10. Competitive Environment and Analysis

10.1. Major Players and Strategy Analysis

10.2. Emerging Players and Market Lucrativeness

10.3. Mergers, Acquisitions, Agreements, and Collaborations

10.4. Vendor Competitiveness Matrix

11. Company Profiles

For more information about this report visit

Laura Wood, Senior Press Manager
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Editor Details

  • Company:
    • Businesswire
Last Updated: 10-Feb-2021